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Inhibition by transforming growth factor (34 43)-a, a
TGF-u antagonist, of gastric carcinogenesis induced by
N-methylh-Nnitro N-nitrosoguanidine in Wistar rats
M Tatsutal, H lishil, M Babal, R Hirasawal, K Iseki2, H Yanol, N Sakai', H Ueharal and A Nakaizumil
Departments of 'Gastrointestnal Oncology and 2Gastroenterology. Osaka Medical Centre for Cancer and Cardiovascular Diseases. Osaka 537. Japan
Summary The effect of prolonged administration of transforming growth factor (34-43)-a, an antagonist of TGF-a. on gastric carcinogenesis
induced by N-methyl-A-nitro-N-nitrosoguanidine (MNNG) and on the labelling and apoptotic indices and TGF-ct immunoreactivity of gastric
mucosa and gastric cancers was examined in Wistar rats. The rats received intraperitoneal injections of 10 or 20 ug kg-' body weight of
TGF(34-43)-ca every other day after oral treatment with MNNG for 25 weeks. Long-term administration of TGF(34-43)-at at both doses
significantly reduced the incidence of gastric cancers at the end of the experiment in week 52. However. TGF(34-43)-a had no significant
effect on the number, histological type or depth of involvement of gastric cancers. Administration of TGF(34-43)-a also significantly
decreased the bromodeoxyuridine labelling index and TGF-a immunoreactivity, and significantly increased the apoptotic index of antral
mucosa and gastric cancers. These findings indicate that TGF(34-43)-a inhibits gastric carcinogenesis, and that its effects are mediated
through decreased cell proliferation and TGF-a immunoreactivity and increased apoptosis induction in the gastric cancers.
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Transforminc growth factor (TGF)-at has multifunctional bio-
logical effects on a variety ofepithelial cells (Liu et al. 1994). It is
a cvtokine that increases cell proliferation and transformation of
x-arious cells Ilihara et al. 1993: Liu et al. 1994: Llio et al. 1995:
Ciacci et al. 1996: Gogusev et al. 1996: Taga et al. 1996).
How-ever. the role that exogenous TGF-a ma) plax in cell prolifer-
ation in Xivo is poorlN understood. Hormi and Lehy 11996) prox ed
for the first time the stimulatorx effect in vivo of exouenous rat
TGF-a on epithelial cell proliferation in antral. duodenal and
colonic mucosae.
Perez-Tomas et al 11992) examined the distribution pattern
of TGF-a in experimental hepatocarcinogenesis induced by
dimethx Initrosamine and found that TGF-a x-as obserxed
immunohistochemicallx in hepatic tumourcells. Wang et al 1996)
also found increased lexels ofTGF-ca mRrNA and protein products
in papillomas and in pronounced hxperplastic and dysplastic
lesions in rats treated with the chemical carcinocen N-nitroso-
methNlbenzvlamine. and concluded that TGF-a may play an
important role in experimental oesophageal tumorigenesis in rats.
Livingstone et al (1994) reported that the carcinogenANT-methx v-V-
nitro-N-nitrosoguanidine (MNNG) caused a significant increase in
the intensity of TGF-a expression in the gastric mucosa after as
little as 16 wxeeks' exposure. These findings indicate that TGF-cx
mav be involx-ed in gastric carcinogenesis. but there wxere no
reports on the possible role of exogenous TGF-a in gastric
carcinogenesis. TGF(34-43 )-c is an antagronist ofTGF-a (Nestor
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et al. 1985). These findings suggest that TGF 34-43a-ct micht
suppress gastric carcinogenesis. To examine this possibilitx. >-e
inxestigated the effect of TGF 34-43)-a on MINNG-induced
gastric carcinogenesis in Wistar rats.
MATERIALS AND METHODS
Animals
Sixtv 6-xweek-old male Wistar rats w-ere purchased from Japan
SLC (Shizuoka. Japan). Two rats each were housed under standard
conditions at a room temperature maintained at 2'1-22-C with a
12-h liahtldark cvcle.
Experimental design
The animals were given MINNG (50 ig ml-': Aldrich Chemical
Co. Milwaukee. W'I. USA) in drinking wxater for 25 Nx-eeks and
regular chox pellets (Nihon Nosan. Yokohama. Japan) oxer the
entire study period. The MNNG x-as dissolved in deionized xwater
at a concentration of 1 mg ml-' and kept in a cool (4 C). dark
place. Just before use. the stock solution >-as diluted to 50PLg ml'
with tap wxater. Forty millilitres of MNNG solution (less than a
single rat consumes in 48 h: this procedure did not affect normal
bodxweight gain) xas rixven to each rat from bottles coxered with
aluminium foil to prexvent photolx-sis of the MNNG. The bottles
were refilled exen- other dav. From wxeek 26. the rats had free
access to ordinary tap water from an automatic wxatering system.
At this point. the animals wxere dixided randomly into three groups
(20 rats in each). Each group receixved i.p. injections even- other
dax until the end ofthe experiment at week 52 as followxs: group 1.
the control group. xxas gixen the xehicle. 0.9%; sodium chloride
solution. only: groups 2 and 3 wxere rixven 10 and 20 lgg kgi body
weight of TGF(31-43- (-C peptide purity > 99%c: Bachem Fine
857858 M Tatsuta et al
Table 1 Incidence and number of gastric cancers and body weight in MNNG-treated rats
Group Trment' Body weight (g) Effective No. of rats No. of gastric
no. no. with gastric cancers per
Initial Week 26 Week 52 of rats cancer (%) tumour-bearing rat
1 Control 102 2 310"±10 343+5 20 19(95) 1.9-0.2
2TGF(34-43)-a 10iugkg-t 101 + 2 290" 8 343 ± 6 20 11 (55)t 2.0 0.3
3TGF(34-43)-o 20 g kg-, 102_3 301 _10 344_6 20 6(30)- 1.8+0.3
aTreatment: after MNNG treatment for 25 weeks. the rats received i.p. injections of 0.5 ml of 0.9°0 sodium chloride solution (group 1). or 10 ug kg-' (group 2) or
20 'g kg-' (group 3) body weight of TFG (34-43)-a in 0.90,% sodium chloride solution every other day until the end of the experiment at week 52. c cSigniffianty
different from the value for group 1: tP < 0.02. cP < 0.001.
Table 2 Histological type and depth of involvement of gastric cancers in MNNG-treated rats
Group Treabtmen No. of Histological type (%) Depth of involvement (%)
no. gastric
cancers Very well-differentiated Well-differentkbted Submucosa Muscle layer
or deeper
1 Control 36 25 (69) 11 (31) 34 (94) 2 (6)
2TGF(34-43)-a 10 ug kg-' 22 18 (82) 4 (18) 22 (100) 0 (0)
3TGF(34-43)-a 20ug kg- 11 10(91) 1 (9) 11 (100) 0(0)
aFor an explanation of treatment. see Table 1.
Chemiicals. Bubendorf. Switzerland) respectively. The TGF(34-
43)-a wvas dissolved in 0.9%e sodium chloride solution just before
use. Injections were given at a volume of 2 ml ko-' body weight
between 14.00 and 15.00 h each day i.p. to strengthen the pharma-
cological action of TGF(34-43i-cx. All experimental procedures
were approved bx the Animal Care Committee of the Osaka
Medical Centre for Cancer and Cardiovascular Diseases.
Histological observations
Animals that survived for more than 50 weeks were included in
the effective numbers because the first tumour of the glandular
stomach was found in a rat in group 1 that died in week 50. All
survivin2 animals were killed and examined at the end of the
experiment at A-eek 52. At necropsv. the stomach and other major
organs wvere subjected to careful macroscopic examination. The
stomach % as opened along the greater curvature. pinned to a cork
mat and fixed with a buffered picric acid-formaldehyde solution.
After processing with a method routinely used for histological
exarirnation. sections were stained with haematoxvlin and eosin.
Sections w-ere examined x ithout know-ledge ofthe group to w-hich
thev belonged.
Definition and classification of gastric cancers
Histolo,icallv. adenocarcinomas w-ere defined as tumours in
which the neoplastic glandular tissue had entered the submucosa
or deeper lavers. As in a previous study (Tatsuta et al. 1988).
adenocarcinomas A-ere subclassified into three types: very Axell-
differentiated. Aell-differentiated or poorly differentiated.
Measurement of the labelling index
The labelling! index of the gastric cancers was measured in
week 52 by assaying bromodeoxvuridine IBrdU) incorporation
(Gratzner. 1982: Morstvn et al. 1983) with an immunohistochem-
ical analx sis kit (Becton Dickinson Immunocytometrx Sy-stems.
Mountain View. CA. USA). Briefly. ten rats from each group w-ere
kept without food for 12 h. and then given i.p. injections of 0.9%7
sodium chloride (group I) or I0jgo kg5-' (group 2) or 20pt ko-'
(group 3) body w-eight ofTGF(3-43)-a. The animals wxere given
i.p. injections of 20 mg kgo' body weight of BrdU 1 h later. and
were then killed with ether after a further hour. The stomachs of
the animals were fixed in 70%e ethanol for 4 h. The fixed stomach
was cut into 3-mm-wide lonaitudinal strips. The specimens were
embedded in paraffin. and sections (3 tm thick) were immersed in
2 N- hN-drochloric acid solution for 30 mmn at room temperature and
then in 0.1 xI sodium borate to neutralize the acid. The sections
were then stained w-ith anti-BrdU monoclonal antibodies (Beckton
Dickinson Immunocytometrv Svstems: diluted 1:100) for 2 h at
room temperature. washed and treated with biotin-conjugated
horse anti-mouse antibodies (diluted 1:200) for 30 min. They were
then stained using the avidin-biotin-peroxidase complex method
(Vector Laboratories) for 30 mmn. The reaction product was local-
ized w-ith 3.3'-diaminobenzidine tetrahydrochloride. The BrdU-
labelled cells were identified by the presence of dark pigment
throughout the nuclei. For antral mucosa. 30 Aell-orientated
glands with the lumen xisible from the bottom to the mucosal
surface and with a single layer of cells along the column of the
gland w-ere selected in lonaitudinal tissue sections. In each
column. the total number of cells (starting from the middle of the
base up to the surface) and the number of labelled cells were
recorded. Totals of about 850-1000 cells per region per rat were
counted. For fundic mucosa. because individual glands are rarely
cut alonc their entire length. labelled and unlabelled epithelial
nucleated cells were counted. using a calibrated ocular grid. in
eight or nine rectangular fields coxering the proliferative zone. At
least 1000 cells were examined per rat. The labelling index of the
gyastric cancers was determined by counting the number of BrdU-
labelled cells in a total of 500 gastric cancer cells. The labellincg
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Table 3 BrdU-Labelling and apoptotic indices of gastric mucosa and gastric cancers in MNNG-treated rats
Group BrdU labelling index (%) Apoptotic index (%) TGF-a immunoreactivity (%)
no. Treatfent
Fundic Antral Gastric Fundic Antral Gastric Fundic Antral Gastric
mucosa mucosa cancer mucosa mucosa cancer mucosa mucosa cancer
1 Control 11.4 1.0 (10): 17.0 + 0.9 (10) 38.2 + 1.4 (5) 7.8 ± 0.6 (10)12.0 0.8 (10) 8.6 ± 0.5 (22) 83.4 ± 1.9 (10) 37.8 -2.1 (10) 64.2 2.2 (22)
2TGF(34-43)-a 10.0_1.4(10) 11.8 0.6:(10) 24.4 1.8 (9) 7.0_0.7(10) 7.8 0.4t(10) 16.8±1.0c(13) 80.8_2.7(10) 27.8 1.2-(10) 49.8+1.3'(13)
10 ug kg-
3TGF(34-43)-a 8.6-1.2(10) 9.4 0.5(10) 18.81.1- (5) 6.0-0.7(10) (10-0.81(10) 19.8-1.7'(6) 79.0-3.3(10) 22.0 1.3 (10) 43.6 3.0c(6)
20 ug kg-
aFor an explanation of treatment. see Table 1. "cSignificantly different from the value for group 1: -P < 0.01. :P < 0.001. :Numbers in parentheses are number of
rats or cancers examined.
index w-as expressed as the percentage of labelled cells amonc the
cells examined.
Measurement of the apoptotic index
The 3'-end labelling ofapoptotic cell DNA Aas performed Aith an
ApopTag in situ apoptosis detection kit (Oncor. Gaithersburg. MD.
USA) (Tormanen et al. 19951. Briefly . after de%vaxing and
dehN-dration. sections were incubated xx ith 20 go ml-' proteinase K
(Boehringer Mannheim. Mannheim. Germanv) at room tempera-
ture for 15 min. Endogenous peroxidase activity was quenched in
2c hydrogen peroxidase in phospate-buffered saline (pH 7.2).
Terminal transferase enzyme was used to catalyse the addition
of digoxigenin-labelled nucleotides to the 3'-hvdroxv ends of
fragmented DNA. Antidigoxigeninm-peroxidase solution was then
applied to the slides. Diaminobenzidine-hydrogen peroxide w-as
used to develop the colour reaction. The specimens were lightly
counterstained with haematoxvlin. The apoptotic index was deter-
mined as described above.
Immunohistochemical observation of TGF-a
Immunohistochermistry was performed with the mouse monoclonal
antibodv AB-2 (Oncogene Science. Cambridge. UK). which is
specific for human and rat TGF-a and exhibits no crossreactivitx to
epidermal growth factor (Lixingstone et al. 1994). Sections were
predigested w-ith trypsin for 15 min to expose the antigenic sites
before incubation with AB-2 at a dilution of 5:100 overnight at
4 C. After washina with Tris-buffered saline. rabbit anti-mouse
serum (Dak-o. UK) and streptavidin-peroxidase complex (Dako)
were added at dilutions of 1:333 and 1:400. respectively. for 30 min
each before application of diaminobenzidine and counterstained
with haematoxy lin. After dehydration in alcohol. the sections w-ere
cleared with xvlene. and mounted in diphthalate xylene. A positixve
control section was incubated in each batch to ensure consistency
of staining. Two txypes of negatixe controls were used: in the first.
the primary antibodxwas replaced by Tris-buffered saline: in the
second. specific controls were performed by preincubation of the
sections with an excess of the TGF-a peptide PF 008 (Oncogene
Science). The relative number of cells that were immunoreactixe
for TGF-a was determined as described aboxe.
Statistical analysis
Statistical analvsis was performed w-ith the chi-squared test.
Fisher's exact probability test. or one-wav analvsis of xariance
w%vith Dunnms multiple comparison (Miller. 1966). Data are
presented as the means ± s.e. Differences with calculated P-x alues
less than 0.05 were regarded as significant.
RESULTS
Incidence, number, histological type and depth of
involvement ofgastric cancers
Administration of TGF(34-43 )-a had no significant effect on the
bodx weiaht of the rats in w-eek 52 (Table 1).
Macroscopically. there xxere no abdominal tissue reactions or
damage as a result ofdirect exposure ofTGF(34-43 -a in week 52.
In group 1 (control). gastric cancers were found in 19 (95%e) of
the 20 rats examined. The incidence of gastric cancers in groups
[TGF(34-43i-a at 10 jgc ko-'] and 3 [TGF(34-43 i-a at 20 k(-']
was significantlv lower than in group 1 (Table 1). In group 1. the
axerage number of gastric cancers per tumour-bearing rat xxwas
1.9 ± 0.2. Howexer. the difference in the number of gastric cancers
amonr the three groups was not significant.
All tumours induced in the glandular stomach were histoloei-
cally determined to be adenocarcinomas (Table 2). Virtuallx all of
the adenocarcinomas were xen- well differentiated. The incidence
of xerv x-ell-differentiated adenocarcinomas was slightly. but not
significantlv. higher in group 3 [TGF(34-43)i-a at 20 jg kg-'] than
in group 1 (control). No poorlv differentiated cancers were found
in this series. Furthermore. neither dose ofTGF 34-43 -a had any
effect on the depth ofMixolxrement ofthe castric cancers (Table 2i.
All cancers were found in the antral mucosa. and no macroscopic
metastases ere seen in any rat.
Labelling and apoptotic indices and TGF-a
immunoreactivity
Administration of TGF(34-43 i-a at 10 jig kgr- (group 2) and
20 ig- kg-l (aroup 3) body xxeight significantl- decreased the BrdU
labelling, index and TGF-a immunoreactixits- and significantly
increased the apoptotic index ofantral mucosa and gastric cancers.
as compared with those in control group 1 (Table 3).
DISCUSSION
There are sexeral reports on transgenic mice oxverexpressing TGF-a.
Takagi et al (1992) and Sharp et al (1995) established a transgenic
line bearing a human TGF-a cDNA driven bx the mouse metallo-
thionein I promoter in the inbred mouse line FVB/N. These mice
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develop severe cystic hyperplasia containing mucus-laden secre-
tions in the fundic mucosa of the stomach. Foci of dysplastic cells
were seen in the lesions of mice surviving until the later stages of
life. However. gastric cancers have neverbeen described until now.
The present study showed that prolonged administration of
TGF(34-43-t. an antagonist of TGF-ac at both high and low
doses significantly decreased the incidence of gastric cancers
induced by MNNG.
The exact mechanism by which TGF(34-43)-a inhibits gastric
carcinogenesis is not clear. but at least two possible explanations
may be considered. One involves the effect of TGF(34-43)-a on
cell proliferation. TGF-a is a cytokine which increases cell prolif-
eration of various cells (Taga et al. 1996). Bishop et al (1995)
found that TGF-a antisense oligodeoxynucleotides markedly
inhibited proliferation of Caco 2 cells. and reported that choles-
terol-modified oligodeoxynucleotides were more effective and
specific than unmodified oligodeoxynucleotides. Seki et al (1997)
reported that culture ofa human hepatocellular carcinoma cell line
(OCUH-16) in the presence of a neutralizing antibody to TGF-a
inhibited cell proliferation. These findings indicate that inhibition
ofTGF-ct may inhibit cell proliferation. The results of the present
work show that long-term administration ofTGF(34-43)-a signif-
icantly decreases the BrdU labelling index ofgastric cancers.
TGF-a stimulates cell proliferation through interaction with its
receptor. the epidermal growth factor receptor. by activating its
tyrosine kinase activities (Wang et al. 1996). Tyrosine kinases are
important in the signal transduction ofa number ofgrowth factors.
In a study of tyrosine phosphorylation in type II pneumocytes
exposed to TGF-c. Chess et al (1994) found that after addition of
TGF-ct phosphorylation of a tyrosine protein with a molecular
mass of 170 kDa. presumed to be the epidermal growth factor
receptor. peaked by 5 min and that the tyrosine kinase inhibitor
genistein and tyrphostin decreased the TGF-a-induced
phosphorylation ofthe epidermal growth factor receptor.
A second possible explanation for the inhibitory effect of
TGF(34-43)-t on gastric carcinogenesis relates to apoptosis. The
integrity of the gastrointestinal mucosa is guaranteed by a regu-
lated balance of proliferation, differentiation and physiological
cell death of its main constituents. Physiological cell death is
known as apoptosis. In a study on the effect of epidermal growth
factor and TGF-a on apoptosis ofan astrocyte progenitor cell line
(AP-16). Yoshida et al (1993) found that epidermal growth factor
deprivation caused the death of AP-16 cells by apoptosis and that
TGF-a prevented apoptosis occurring in the absence ofepidermal
growth factor. Reinartz et al (1996) reported that induction of
apoptosis by tumour necrosis factor-a in the human keratinocyte
cell line HaCaT was reduced by preincubation of the cells with
TGF-a and that the protective effect of TGF-a was abrogated by
translation inhibition. indicating that it depended on de novo
protein synthesis. More recently. Seki et al (1997) also found that
culture of cells in the presence of a neutralizing antibody to TGF-
a induced apoptosis oflarge numbers ofcells. The findings ofthe
present study show that prolonged administration of TGF(34-
43)-a significantly increases the frequency ofapoptosis induction
in gastric cancers. Increased induction of apoptosis decreases the
susceptibility ofan individual to malignancy.
The results presented indicate that administration of TGF(34-
43)-a inhibits the development ofgastric cancers. and that inhibi-
tion of gastric carcinogenesis by TGF(34-43)-ct may be mediated
by decreased cell proliferation and TGF-a immunoreactivity and
enhanced induction ofapoptosis.
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